Anima Biotech brings mRNA biology modulators to AbbVie against oncology and immunology targets
A USD $42 million collaboration between AbbVie and Anima Biotech aims to leverage the latter’s mRNA Lightning technology platform to enhance therapeutic development programs in oncology and immunology.
Pharmaceutical giant AbbVie and biotech innovator Anima Biotech have announced a collaboration for the discovery and development of mRNA biology modulators across oncology and immunology, taking advantage of Anima’s mRNA Lightning platform.
Anima’s platform provides differentiated approaches towards the discovery of small molecule mRNA drugs and mechanisms of action. By combining high-scale phenotypic screening, experiments involving live mRNA biology are automated with MOAi technology utilising artificial intelligence to determine the mechanism of action for active molecules, allowing for a broad pipeline development for 18 different therapeutic discovery programs. The mRNA Lightning platform will provide AbbVie exclusive rights to license, develop, and commercialise these programs.
AbbVie is set to give an upfront payment of USD $42 million with eligibility to receive up to USD $540 million in option fees and R&D milestones across three targets. Further commercial achievements may also result in tiered royalties on net sales. AbbVie will also have an option to expand the collaboration for up to three additional therapeutic targets under the same terms and conditions.
In a statement, VP and Global Head of Discovery Research at AbbVie Jonathon Sedgwick commented: “This collaboration will give AbbVie access to Anima’s leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie’s world class capabilities in discovering and developing drugs to make a difference in patient’s lives. Modulating mRNA biology with small molecules is a new approach and has the potential to address ‘undruggable’ targets with implications across multiple therapy areas.”
Co-founder and CEO of Anima Yochi Slonim added: “Anima’s differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline. We are excited to partner with AbbVie, a recognised global leader in oncology and immunology, and are looking forward to start working with their excellent scientific team in a close collaboration.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance